UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K/A
(Amendment No. 1)
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 31, 2004
Date of Filing: April 2, 2004
Lynx Therapeutics, Inc.
Delaware
(State or Other Jurisdiction of Incorporation)
| 0-22570 | 94-3161073 | |
| (Commission File No.) | (IRS Employer Identification No.) |
25861 Industrial Blvd.
Hayward, California 94545
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (510) 670-9300
| Item 12. Results of Operations and Financial Condition | ||||||||
| SIGNATURE | ||||||||
| INDEX TO EXHIBITS | ||||||||
| EXHIBIT 99.1 | ||||||||
The purpose of this Current Report on Form 8-K/A is to amend the Registrant’s Current Report on Form 8-K, dated March 31, 2004 and filed with the Securities and Exchange Commission on March 31, 2004, relating to the press release announcing financial results for the fourth quarter and fiscal year 2003. This Report amends and restates the information provided under Item 12.
Item 12. Results of Operations and Financial Condition
On March 31, 2004, Lynx Therapeutics, Inc. issued a press release announcing financial results for the fourth quarter and fiscal year 2003. A copy of such press release, entitled “Lynx Announces 2003 Fourth Quarter and Full Year Financial Results,” is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Lynx Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| LYNX THERAPEUTICS, INC. |
||||
| Dated: April 2, 2004 | By: | /s/ Kevin P. Corcoran | ||
| Kevin P. Corcoran | ||||
| President and Chief Executive Officer (Principal Executive Officer) |
||||